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AbstrAct
Background Cytosine arabinoside (CA) and prednisolone 
are drugs commonly used together in the management 
of canine non-infectious meningoencephalitis (NIME). 
The aim of this study was to report the haematological 
findings before and after CA and prednisolone treatment 
and identify any adverse haematological events in this 
clinical setting, following the veterinary cooperative 
oncology group established common terminology criteria 
for recording adverse events following administration of 
chemotherapy or biological antineoplastic therapy.
Results While 48 patients with a presumptive diagnosis 
of NIME had pretreatment haematology results, only 12 
patients met the inclusion criteria of also having post-
treatment haematology results available for review after 
being treated with prednisolone and CA at a standard dose 
(200 mg/m2) in a single referral hospital in the UK. Forty-
nine post-treatment haematology results were available 
for these 12 patients.
Conclusions Four adverse haematological events were 
identified in four patients. None of these events were 
convincingly attributable to CA administration.
IntRoduCtIon
Non-infectious meningoencephalitis (NIME) 
is a term used to characterise inflamma-
tory brain diseases for which no underlying 
infectious agent is identified and when an 
immune-mediated basis is suspected.1–4 The 
terms meningoencephalitis of unknown 
origin (MUO)3 or meningoencephalitis of 
unknown aetiology are also commonly used 
as the pathophysiology of NIME is still poorly 
understood.5 A histopathological diagnosis 
is necessary to reach a definitive diagnosis 
(eg, granulomatous meningoencephalitis, 
necrotising leukoencephalitis or necrotising 
meningoencephalitis); however, a presump-
tive diagnosis is often made based on signal-
ment, neurological examination, advanced 
imaging, cerebrospinal fluid analysis and 
infectious disease testing.1 2 5–9 There remains 
considerable debate regarding what consti-
tutes the preferred treatment for cases diag-
nosed with NIME.3 10–14 Treatment is centred 
on immunosuppression and while multiple 
protocols are available, few comparative 
studies have been published.3 Prednisolone 
monotherapy and cytosine arabinoside 
(CA) alongside prednisolone are two of the 
immunosuppressive protocols of choice for 
the treatment of NIME,10 13 with one recent 
study suggesting that early treatment with a 
constant rate infusion (CRI) of CA could 
reduce the early mortality associated with the 
disease.14 CA, an S-phase, cell cycle-specific 
cytotoxic agent, is converted on entering cells 
to the active form arabinosylcytosine triphos-
phate. Several mechanisms of action have 
been proposed to explain its cytotoxic activity 
including inhibition of DNA polymerase 
α and incorporation into the DNA strand. 
The overall result being inhibition of DNA 
synthesis.15 As a cytotoxic drug, CA exerts its 
effects on all proliferating cells, such as the 
haematopoietic progenitor cells in the bone 
marrow, and this can lead to myelosuppres-
sion. In dogs, the time to maximal myelosup-
pression (nadir) following CA administration 
alone is considered to be close to 8–10 days 
after treatment.16 
There are limited reports in the literature 
regarding adverse effects; however, anec-
dotally, there would appear to be very few 
adverse events when using CA. Potential 
adverse reactions reported in association 
with CA use include dermatological disease 
following subcutaneous injections in dogs 
treated for NIME17 18 and infiltrative lung 
disease.19 The incidence of myelosuppression 
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following CA administration for the treatment of canine 
lymphoma (600 mg/m2 intravenously over 48 hours) has 
been assessed in a previous publication, and their results 
showed that 10 of 14 patients developed at least one cyto-
penia.20 While the risk of haematological adverse events 
following the administration of prednisolone and CA at 
the dose of 200  mg/m2 seems to be very low, few clinical 
studies have reported on the safety of this protocol in the 
treatment of NIME.10 14 21 In those studies, pretreatment 
haematology results were not reported in detail, and the 
post-treatment haematology was either performed three 
weeks after CA administration,14 was not performed in 
all dogs21 or was not described in enough detail to docu-
ment potential side effects.10 More recently, a study 
evaluating the pharmacokinetics of CA alone in a popu-
lation of healthy animals used at 200 mg/m2 (either over 
48 hours as subcutaneous injections or over eight hours 
as an intravenous CRI) reported that all six patients 
included in the study had haematological parameters 
within normal limits before treatment and seven days 
after CA administration.22
The aim of our study was to estimate the prevalence of 
pretreatment and post-treatment haematological abnor-
malities in patients with a presumptive diagnosis of NIME 
treated with a combination of prednisolone and CA.
Methods
study design
This was a retrospective, descriptive, single-centre study 
performed at a university referral hospital in the UK 
between 2010 and 2016. All patients were client-owned 
dogs. The clinical database, client and referring veteri-
narian communications were searched for patients who 
received CA between 2010 and 2016.
Inclusion and exclusion criteria
To be included in this study, patients had to have been 
referred to the hospital with neurological signs and have 
undergone investigations leading to a presumptive diag-
nosis of NIME made by a board-certified neurologist or 
a resident working under their guidance. A presump-
tive diagnosis of NIME was reached based on patients 
fulfilling the criteria set out in previous publications 
including neurological examination findings, MRI or CT 
findings, infectious diseases testing and, when safe, cere-
brospinal fluid analysis (CSF).3 All patients had to have 
received corticosteroids and CA as part of their treatment 
protocol for NIME. The total CA dose administered for 
each treatment had to be 200 mg/m2. This had to be given 
either as an intravenous CRI given over 8–24 hours, or via 
four 50 mg/m2 subcutaneous injections at 12-hour inter-
vals. Data regarding age, sex, breed, pretreatment and 
post-treatment haematology results were obtained. A 
complete pretreatment haematology performed in the 
four weeks prior to CA administration had to be avail-
able for review. However, only the haematocrit or packed 
cell volume, neutrophil count and platelet count were 
recorded and examined for the purpose of the study, 
using a similar approach evaluated in a previous study.20 
A platelet count that fell below the machine reference 
interval had to be confirmed with a manual blood film 
evaluation and platelet count. Additionally, the date 
of CA administration and the date of post-treatment 
haematology assessment was recorded. All post-treatment 
haematology assessments had to be performed 5–14 days 
following CA administration. The dose in mg/kg of pred-
nisolone was recorded at each haematological assess-
ment. Haematology assessments were performed either 
at the referral hospital, an external laboratory or at the 
referring veterinary clinic. Reference ranges were there-
fore not all the same.
Exclusion criteria included: any patient receiving a drug 
other than CA that was known to have a direct myelosup-
pressive effect; any patient receiving a different dose of 
CA; any patient for whom the pretreatment or post-treat-
ment haematology results could not be reviewed. Patients 
receiving drugs reported to cause idiosyncratic haemato-
logical abnormalities (eg, phenobarbitone or trimetho-
prim-sulphonamide) were not excluded.
Grading of adverse effects
Each post-treatment haematology report was consid-
ered an event. Each event was individually graded using 
the established veterinary cooperative oncology group - 
common terminology criteria for adverse events (VCOG-
CTCAE) haematological grading system.23
Results are reported as frequencies using numbers and 
percentages with 95 per cent confidence interval (CI)
where appropriate.
Results
Seventy-four patients were initially identified. Sixty-two 
patients were excluded: 19 cases did not have MUO 
as their final diagnosis. Of the remaining 55 cases, 48 
had a pretreatment haematology available for review 
(online supplementary file 1). Only 12 cases received the 
standard dose of 200 mg/m2 of CA and had a pretreat-
ment and post-treatment haematology available for 
review (online supplementary file 2).
Of these 12 cases, the following breeds were included: 
two Chihuahuas, two West Highland white terriers, two 
shih tzus, two labradors, a Maltese, a bull terrier, a whippet 
and an Airedale terrier. Median age was 77.5 months 
(range 10–131 months). Neutering status included: seven 
neutered females, three neutered males, one entire male 
and one entire female (table 1).
haematology results at diagnosis
Forty-eight patients with a diagnosis of NIME that subse-
quently received CA administration had a haematology 
at diagnosis available for review (online supplementary 
file 1). In six patients (12.5 per cent, 95 per cent CI 5 
to 26), the haematocrit was outside the reference range. 
Anaemia was recorded in four patients and erythrocy-
tosis in two patients. Although 28 patients (58 per cent, 
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95 per cent CI 9 to 33) had an abnormality noted on 
their leucogram, only nine patients (18.8 per cent, 
95 per cent CI 43 to 72) had either a leucocytosis (5/9) or 
leucopenia (4/9) reported. Six patients (12.5 per cent, 
95 per cent CI 5 to 26) were reported to have either a 
thrombocytosis (5/6) or thrombocytopenia (1/6). In the 
single patient with a thrombocytopenia on the machine 
count, no blood smear or manual platelet count were 
performed.
Post-treatment haematology results
Twelve patients included in the study received a total 
of 49 standard CA treatments for which the post-treat-
ment haematology reports were available for review 
(online supplementary file 2). The median time from CA 
administration to post-treatment haematology assessment 
was 7 days (range 6–13 days). Nine (18 per cent) of these 
49 treatments were administered as a CA intravenous 
CRI given over a period between 8 hours and 24 hours. 
The remaining 42 (82 per cent) treatments were given 
as subcutaneous injections of CA over 48 hours. Of the 
49 post-treatment haematology results available to review, 
we identified four (8 per cent, 95 per cent CI 3 to 21) 
instances of an adverse haematological event in four 
patients (33per cent, 95per cent CI 11 to 65), and this 
was anaemia in each instance (online supplementary 
file 3), as determined by the VCGO-CTCAE haemato-
logical toxicity grading system (online supplementary 
file 2). Patient 3 who had been noted to have a border-
line non-regenerative anaemia prior to treatment was 
documented to have a persistent mild non-regenerative 
anaemia following their first CA treatment equating to 
VCGO-CTCAE grade 1. Patient 4 was noted to develop 
a mild anaemia equating to VCGO-CTCAE grade 1 
following their first CA treatment. Patient 9 developed 
a moderate anaemia which was markedly regenerative 
and a thrombocytosis following their third CA treat-
ment equating to VCGO-CTCAE grade 2. Patient 11 
developed a mild non-regenerative anaemia equating to 
VCGO-CTCAE grade 1 following their first CA treatment. 
Taking these factors into consideration, a total of four 
haematological abnormalities were identified over 49 
events. Prednisolone dose and concurrent medications 
were recorded for each patient at the time of the haema-
tology assessment (online supplementary file 2).
dIsCussIon
The incidence of haematological abnormalities in 
patients with a presumptive diagnosis of NIME is sparsely 
documented in the current veterinary literature.3 5–8 10–14 24 
A unique aspect of this study is the review of the haema-
tological findings at diagnosis of a group of patients with 
presumptive NIME subsequently treated with predni-
solone and a standard dose of CA. While abnormalities 
of the leukogram at diagnosis were not uncommon in 
our patient population, some of the changes could be 
explained by the recent administration of corticoster-
oids either at anti-inflammatory or immunosuppressive 
doses (4/8 cases presented with a neutrophilia were 
receiving corticosteroids at the time of haematological 
testing; online supplementary file 1).
Administration of cytotoxic agents comes with the risk 
of adverse events particularly haematological toxicity. 
Table 1 Descriptive data for the 12 patients undergoing therapy with a standard dose of cytosine arabinoside, including 
concurrent therapy over the course of treatment
Patient 
number
Age at diagnosis
(months) Sex Breed Concurrent drugs
1 72 FN Chihuahua Prednisolone, trimethoprim-sulphonamide, omeprazole, sucralfate, 
clindamycin and topical chloramphenicol eye-drops.
2 131 MN West Highland white 
terrier
Prednisolone, omeprazole, levetiracetam, topical miconazole nitrate, 
prednisolone acetate and polymxyin B sulfate.
3 61 FN shih tzu Prednisolone, cyclosporine and cephalexin.
4 52 FN Maltese Prednisolone and cyclosporine.
5 16 ME Chihuahua Prednisolone, doxycycline, phenobarbitone, levetiracetam and cyclosporine.
6 112 FN shih tzu Prednisolone.
7 96 MN West Highland white 
terrier
Prednisolone, cephalexin, theophylline and topical fusidic acid.
8 57 FN whippet Prednisolone, phenobarbitone, potentiated amoxicillin, metronidazole, 
sucralfate and cimetidine.
9 119 FN Airedale Prednisolone.
10 83 FN Labrador Prednisolone, phenobarbitone, potentiated amoxicillin, omeprazole, 
sucralfate and maropitant.
11 10 FE Labrador Prednisolone, potentiated amoxicillin and omeprazole.
12 115 MN bull terrier Prednisolone.
FE, female entire; FN, female neutered; ME, male entire; MN, male neutered.
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Assessment of 49 post-treatment haematology reports 
identified four haematological abnormalities following 
CA administration.
The four adverse events included a mild anaemia 
in three patients after their first CA treatment and a 
moderate anaemia in one patient following their third CA 
treatment. In all cases, confounding factors meant that 
the anaemia could not be definitively attributed to CA 
administration. Confounding factors included suspected 
gastrointestinal bleeding and, in one patient, exploratory 
laparotomy. In each case, the mild-to-moderate anaemia 
although not directly attributable to CA treatment may 
have had a slower resolution due to the myelosuppressive 
effect of CA on erythropoiesis. Three of these four cases 
were patients who had received intravenous CA adminis-
tration. The significance of this finding is unknown and 
could be the grounds for a future prospective study.
There are limitations to this study, due to its retrospec-
tive nature and due to the inclusion criteria resulting in a 
small number of patients being eligible for review. Addi-
tionally, ideally, we would have evaluated a population 
of canine patients diagnosed with NIME receiving only 
CA and prednisolone. However, given the retrospective 
nature of our study this was not possible. Our exclusion 
criteria dictated that patients receiving drugs known to 
have myelosuppressive effects were excluded. Ultimately, 
no patients were excluded due to this criterion; however, 
all patients received additional drugs, for example, anaes-
thetic agents or intravenous fluids in the course of their 
investigations and treatment. Many patients in our popu-
lation also required adjunctive therapy in the manage-
ment of their concurrent clinical signs, for example, 
omeprazole or antiseizure medication, for example, 
phenobarbitone, the latter of which has been reported to 
cause idiosyncratic reactions. As we had a plausible expla-
nation for all post-treatment haematological abnormali-
ties identified, we did not consider that concurrent drug 
administration was a contributing factor to any post-treat-
ment haematological abnormalities.
As outlined above, our results support that the myelo-
suppressive effect of CA at this dose appears low. Being a 
retrospective study, we could not standardise the labora-
tories used, resulting in some haematology testing being 
performed in-house, while others were performed in 
external laboratories. As age, sex and breed are known 
to affect haematological parameters and given the small 
and diverse patient population in our study, any statis-
tical comparison was considered inappropriate.25–28 
A larger prospective study with rigorous standardisa-
tion of the timing and methodology of haematological 
assessment following CA administration would provide a 
more accurate quantification of the adverse event rate. 
All post-treatment haematology assessments in our study 
were performed between 6 days and 12 days following 
CA administration, that is, close to the expected 
nadir. However, a limitation resides in the fact that the 
post-treatment haematology assessment may have missed 
the nadir for some patients leading to a false negative 
result for an adverse haematological event. Lastly, we did 
consider the possibility of including a control group of 
NIME patients treated with prednisolone only. However, 
patients treated with corticosteroid monotherapy do not 
have routine haematology performed during their treat-
ment; therefore, it was not possible to retrospectively 
provide a matched control group. This could be consid-
ered if a future prospective study was designed.
Our small study population reflects our inclusion and 
exclusion criteria and limits the conclusions we can draw. 
We concluded that routine post-treatment haematology 
assessment following administration of 200 mg/m2 CA in 
dogs identified four adverse haematological events, two 
of which were attributed to prednisolone induced gastro-
intestinal bleeding. Further studies would be needed to 
determine if our findings can be extrapolated to a larger 
population of NIME patients receiving CA and prednis-
olone therapy.
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